Does hydroxyurea prevent pulmonary complications of sickle cell disease?

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):432-7. doi: 10.1182/asheducation-2014.1.432. Epub 2014 Nov 18.

Abstract

A 27-year-old man with sickle cell disease (HbSS) presents to the sickle cell clinic for follow-up after a screening echocardiogram revealed an increased tricuspid regurgitant velocity of 2.7 m/s. He has a history of 2 painful crises per year and has been hospitalized 3 times over the past 10 years for management of painful crises. He had one episode of acute chest syndrome at age 15 that was treated with an RBC exchange transfusion, supplemental oxygen, and intravenous antibiotics; he did not require mechanical ventilation. He has not had additional episodes of acute chest syndrome and does not have a history of stroke, retinopathy, or leg ulcers. The patient has never been treated with hydroxyurea. He wants to know whether hydroxyurea will prevent future pulmonary complications related to sickle cell disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / drug therapy*
  • Humans
  • Hydroxyurea / therapeutic use*
  • Lung Diseases / etiology*
  • Lung Diseases / prevention & control*
  • Practice Guidelines as Topic
  • Publications

Substances

  • Hydroxyurea